K. Heimersson

发表

Nicotinamide inhibits endotoxin‐induced monocyte tissue factor expression

J. Ungerstedt, K. Heimersson, T. Söderström, 2003, Journal of thrombosis and haemostasis : JTH.

Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia

R. Månsson, C. I. Smith, R. Zain, 2021, HemaSphere.

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers

R. Rosenquist, E. Young, A. Österborg, 2016, Haematologica.

Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment

R. Månsson, K. Heimersson, M. Andersson, 2022, HemaSphere.

Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease‐negativity in the bone marrow of poor‐prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections – Results from a phase I study

A. Österborg, J. Lundin, H. Mellstedt, 2018, British journal of haematology.

Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients

A. Österborg, F. Mozaffari, I. Eriksson, 2018, European journal of haematology.

Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients

A. Österborg, I. Eriksson, H. Mellstedt, 2014 .

Temporary cessation of ibrutinib results in reduced grade 3‐4 infections and durable remissions—Interim analysis of an on‐off‐repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia

A. Österborg, J. Lundin, H. Mellstedt, 2021, EJHaem.